What is Trazodone Hydrochloride Market?
Trazodone Hydrochloride is a stimulant medication that works to balance chemicals in the brain. It's used to treat depression, tension, or a mix of sadness and uneasiness. It can help individuals having issues like low disposition, helpless rest, and helpless focus. As indicated by the World Health Organization (WHO), in 2017, around 300 million individuals are assessed to be influenced by misery, internationally. Moreover, WHO passed a World Health Assembly goal in 2013, to address mental problems in an extensive and facilitated way and has secured melancholy under its Mental Health Gap Action Program. As per the Anxiety and Depression Association of America (ADAA), a significant depressive issue is the main source of incapacity in the U.S., among individuals matured between 15 years and 44.3 years, and influences around 6.7% of the U.S. populace matured 18 years or more. The developing number of cases experiencing misery is one of the significant driving components of the development of the market.
The market study is being classified by Type (Tablet and Capsule), by Application (Antidepression, Anxiolytic, Hypnotic and Others) and major geographies with country level break-up.
Mylan (United States), Fermion(Finland), The Piramal Group (India), Angelini Group (Italy) and Teva Pharmaceuticals(Israel) are some of the key players profiled in the study.
Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Trazodone Hydrochloride market throughout the predicted period.
Segment Analysis
Analyst at AMA have segmented the market study of Global Trazodone Hydrochloride market by Type, Application and Region.
On the basis of geography, the market of Trazodone Hydrochloride has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Market Drivers
- The increasing prevalence of mental disorders such as depression and anxiety is expected to boost the trazodone hydrochloride market growth over the forecast period
- increased suicidal tendency worldwide
- Growing the risk of suicidal thoughts and behaviors in pediatric and young adult patients
Restraints
- Strict patent regulations
Opportunities
- increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients is booming the market opportunities
Challenges
- The adverse effect of using Trazodone Hydrochloride
Market Leaders and some development strategies
In June 2020 Italy based company Angelini Pharma announced its acquisition with ThermaCare. The deal also includes the dedicated US manufacturing site for ThermaCare in Albany, Georgia. The acquired asset supports Angelini Pharma reinforcing both its Consumer Healthcare business and consolidating its international presence .
Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Trazodone Hydrochloride Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End Use Industry